Mesoblast leads the pack with 8.7% share price gain
MELBOURNE: Stem cell treatments maker Mesoblast finished today’s session up 8.7 per cent ... read more
Intelicare flags major traction from recent marketing drive
PERTH: Health tech company InteliCare Holdings (ASX:ICR) has provided a market update today ... read more